{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:02:11Z","timestamp":1762254131850,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-022-00599-5","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T10:09:45Z","timestamp":1650622185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Computational drug repurposing in the age of COVID-19: mixing antiviral cocktails in silico"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-4339","authenticated-orcid":false,"given":"James A.","family":"Diao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8050-9402","authenticated-orcid":false,"given":"Marium M.","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik P.","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7517-2291","authenticated-orcid":false,"given":"Joseph C.","family":"Kvedar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"599_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) dashboard. https:\/\/covid19.who.int\/ (2019)."},{"key":"599_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez, J. J. et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front. Oncol. 7, 273 (2017).","journal-title":"Front. Oncol."},{"key":"599_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41746-022-00561-5","volume":"5","author":"R Howell","year":"2022","unstructured":"Howell, R. et al. Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. NPJ Digit Med 5, 18 (2022).","journal-title":"NPJ Digit Med"},{"key":"599_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/978-3-642-31424-7_50","volume":"18","author":"D Benque","year":"2012","unstructured":"Benque, D. et al. BMA: Visual tool for modeling and analyzing biological networks. Comput. Aided Verif 18, 686\u2013692 (2012).","journal-title":"Comput. Aided Verif"},{"key":"599_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41568-020-0258-x","volume":"20","author":"MA Clarke","year":"2020","unstructured":"Clarke, M. A. & Fisher, J. Executable cancer models: successes and challenges. Nat. Rev. Cancer 20, 343\u2013354 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"599_CR6","doi-asserted-by":"publisher","unstructured":"Jin, W. et al. Deep learning identifies synergistic drug combinations for treating COVID-19. Proc. Natl. Acad. Sci. USA https:\/\/doi.org\/10.1073\/pnas.2105070118 (2021).","DOI":"10.1073\/pnas.2105070118"},{"key":"599_CR7","doi-asserted-by":"publisher","unstructured":"Ahmed, M. et al. Identification of atovaquone and mebendazole as repurposeddrugs with antiviral activity against SARS-CoV-2 (Version 6). ChemRxiv https:\/\/doi.org\/10.26434\/chemrxiv-2021-b3fv1-v7 (2021).","DOI":"10.26434\/chemrxiv-2021-b3fv1-v7"},{"key":"599_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes, J. P., Rees, S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharmacol. 162, 1239\u20131249 (2011).","journal-title":"Br. J. Pharmacol."},{"key":"599_CR9","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/S2213-2600(21)00270-8","volume":"9","author":"P Venkatesan","year":"2021","unstructured":"Venkatesan, P. Repurposing drugs for treatment of COVID-19. Lancet Respir. Med 9, e63 (2021).","journal-title":"Lancet Respir. Med"},{"key":"599_CR10","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30\u2013e31 (2020).","journal-title":"Lancet"},{"key":"599_CR11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S2213-2600(21)00358-1","volume":"9","author":"AC Kalil","year":"2021","unstructured":"Kalil, A. C. & Stebbing, J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet. Respir. Med. 9, 1349\u20131351 (2021).","journal-title":"Lancet. Respir. Med."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00599-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00599-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T07:55:18Z","timestamp":1669362918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-022-00599-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1038\/s41746-022-00599-5","relation":{},"ISSN":["2398-6352"],"issn-type":[{"type":"electronic","value":"2398-6352"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"20 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C.K. is the Editor-in-Chief of npj Digital Medicine. J.A.D. was previously employed by PathAI, Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}